NEW YORK and NEW ORLEANS, July 14, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. (“ADMA” or the “Company”) (NasdaqGM: ADMA) of a class action securities lawsuit.

globenewswire.com - 2026-07-14 22:41:00

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA).   Such investors are advised to contact Danielle Peyton at  [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

globenewswire.com - 2026-07-14 17:30:00

New York, New York--(Newsfile Corp. - July 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-07-14 12:37:00

NEW YORK, July 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

prnewswire.com - 2026-07-14 10:07:00

Jerrold V. Grossman, ADMA Biologics co-founder and Vice Chairman, signed annual reports that allegedly concealed channel stuffing and an undisclosed related party distributor operating from ADMA's own headquarters.

globenewswire.com - 2026-07-14 10:05:00

SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captioned Mazzarino v.

globenewswire.com - 2026-07-14 07:45:00

A securities fraud class action lawsuit has been filed on behalf of ADMA Biologics investors after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws. NEW YORK, July 14, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP  announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

prnewswire.com - 2026-07-14 06:21:00

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

globenewswire.com - 2026-07-13 19:21:00

Adma Biologics (ADMA) closed the most recent trading day at $8.97, moving 1.21% from the previous trading session.

zacks.com - 2026-07-13 18:51:19

BENSALEM, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

globenewswire.com - 2026-07-13 13:15:00

New York, New York--(Newsfile Corp. - July 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-07-13 12:31:00

New class action for ADMA Biologics (ADMA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 8/10/2026

globenewswire.com - 2026-07-13 12:00:00

New York, New York--(Newsfile Corp. - July 13, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law

feeds.newsfilecorp.com - 2026-07-13 12:00:00

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

zacks.com - 2026-07-13 10:32:03

Pension funds and asset managers holding ADMA Biologics positions during the Class Period face potential fiduciary exposure as alleged channel stuffing scheme inflated ASCENIV revenues from $92.6 million to $362.5 million over two years. Pension funds and asset managers holding ADMA Biologics positions during the Class Period face potential fiduciary exposure as alleged channel stuffing scheme inflated ASCENIV revenues from $92.6 million to $362.5 million over two years.

globenewswire.com - 2026-07-13 10:00:00

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.

globenewswire.com - 2026-07-13 06:20:00

ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA PR Newswire

gurufocus.com - 2026-07-13 05:00:00

LOS ANGELES, July 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA " or "the Company") (NASDAQ: ADMA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

prnewswire.com - 2026-07-13 04:40:00

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire

gurufocus.com - 2026-07-13 04:00:00

LOS ANGELES, July 13, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2024 and March 25, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before August 10, 2026.

prnewswire.com - 2026-07-13 03:26:00

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm PR Newswire

gurufocus.com - 2026-07-12 20:00:00

NEW YORK, July 12, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

prnewswire.com - 2026-07-12 19:57:00

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 12, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. ("ADMA Biologics" or the "Company") (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

newsfilecorp.com - 2026-07-12 10:13:00

New York, New York--(Newsfile Corp. - July 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-07-12 08:19:00

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options

globenewswire.com - 2026-07-11 08:19:00

ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action La

gurufocus.com - 2026-07-10 23:00:00

NEW ORLEANS, July 10, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against ADMA Biologics, Inc. (NasdaqGM: ADMA) ("ADMA" or the "Company"), if they purchased or otherwise acquired the Company's securities between August 9, 2024 and March 25, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of New Jersey.

prnewswire.com - 2026-07-10 22:00:00

NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

globenewswire.com - 2026-07-10 14:48:00

LOS ANGELES, July 10, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming August 10, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”).

globenewswire.com - 2026-07-10 13:56:00

New York, New York--(Newsfile Corp. - July 10, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ADMA securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period").

newsfilecorp.com - 2026-07-10 12:00:00

Philadelphia, Pennsylvania--(Newsfile Corp. - July 10, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company") on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired ADMA securities during the Class Period may, no later than August 10, 2026, seek to be appointed as a lead plaintiff representative of the class.

newsfilecorp.com - 2026-07-10 09:21:00

NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

globenewswire.com - 2026-07-10 09:00:00

LOS ANGELES, July 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. (“ADMA” or “the Company”) (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before August 10, 2026.

globenewswire.com - 2026-07-10 08:50:00

ADMA Biologics (NASDAQ:ADMA) Channel Stuffing Claims Trigger Securities Fraud Class Action – Investors Notified to Contact BFA Law about the Lawsuit

globenewswire.com - 2026-07-10 06:20:00

New York, New York--(Newsfile Corp. - July 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-07-09 18:54:00

NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

prnewswire.com - 2026-07-09 17:23:00

LOS ANGELES, July 9, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) have opportunity to lead the securities fraud class action lawsuit.

prnewswire.com - 2026-07-09 15:32:00

ADMA Investor Alert: ADMA Biologics, Inc. Investors with Large Losses Should Contact Robbins LLP for Information About Representing the Shareholder Class

globenewswire.com - 2026-07-09 15:13:00

New class action for ADMA Biologics (ADMA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 8/10/2026

globenewswire.com - 2026-07-09 12:00:00

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. ("ADMA Biologics" or the "Company") (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

newsfilecorp.com - 2026-07-09 11:33:54

NEW ORLEANS, La., July 09, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against ADMA Biologics, Inc. (NasdaqGM: ADMA) (“ADMA” or the “Company”), if they purchased or otherwise acquired the Company's securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.

globenewswire.com - 2026-07-09 11:21:00

Levi and Korsinsky, LLP encourages investors who suffered losses in ADMA Biologics, Inc. (NASDAQ: ADMA) to contact the firm. Those who purchased ADMA securities b

gurufocus.com - 2026-07-09 11:00:00

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP encourages investors who suffered losses in ADMA Biologics, Inc. (NASDAQ: ADMA) to contact the firm. Those who purchased ADMA securities between August 9, 2024 and March 25, 2026 may be entitled to recover damages. Find out if you are eligible to recover losses or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.August 8, 2024. ADMA files its Q2 2024 Report disclosing purchases from GenesisBPS but omitting sales to Gen.

businesswire.com - 2026-07-09 10:07:00

NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) of the  August 10, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The ADMA Class Action Lawsuit : Do you, or did you, own shares of ADMA Biologics, Inc. (NASDAQ: ADMA)?

globenewswire.com - 2026-07-09 09:19:00

SAN DIEGO, July 9, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit.  Captioned Mazzarino v.

prnewswire.com - 2026-07-09 08:30:00

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 8, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.

newsfilecorp.com - 2026-07-08 21:57:00

New York, New York--(Newsfile Corp. - July 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

newsfilecorp.com - 2026-07-08 17:49:00

ADMA shares rebound 13.5% in a month after a steep decline, even as lowered 2026 guidance and IG market competition continue to weigh on sentiment.

zacks.com - 2026-07-08 15:05:21

LOS ANGELES, July 08, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

globenewswire.com - 2026-07-08 12:07:00

ADMA Biologics projected 20% ASCENIV revenue growth in 2025, but a short-seller report alleges the real figure was a 3% decline, with the gap driven entirely by an alleged channel stuffing scheme. NEW YORK, July 8, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP highlights the contrast between ADMA Biologics, Inc.'s (NASDAQ: ADMA) public growth projections and the results alleged by independent research.

prnewswire.com - 2026-07-08 10:11:00